

CareNet forms capital and business alliance with CellGenTech, Inc.

March 19, 2019

CareNet, Inc.

CareNet Inc. (headquarters: Chiyoda-ku, Tokyo; President: Katsuhiko Fujii; URL: <http://www.carenet.co.jp>, hereinafter CareNet) announces that CareNet will form a capital and business alliance with CellGenTech, Inc. (headquarters: Chuo-ku, Chiba-city; President: Masashi Aso; URL: <http://www.cellgentech.com/>; hereinafter CellGenTech).

【Reasons for the capital and business alliance】

As a result of the global active research and development of regenerative medicines in the 21st century, many of these have been approved and launched as pharmaceutical products recently, and are expected further increase in the future. Such regenerative medicine products have different clinical application by the types of cells used and the practical use of products from various cells are being researched and developed.

Regenerative medicine developed by CellGenTech is to treat orphan diseases and refractory diseases using “fat cells”, unlike iPS cells or ES cells. This treatment method extracts the fat cells that all patients have, processes the fat cells by introducing the gene for secretion of the therapeutic protein into the cells (GMAC: Genetically Modified Adipocyte), and administers them to the patient. Possible indications are refractory diseases due to enzyme deficiency (LCAT deficiency and lysosomal disease) and orphan diseases such as hemophilia. The therapy is expected to supplement genetically deficient genes.

In the development of such products, on the other hand, despite having promising technologies venture companies have problems with marketing resources. CareNet reached agreement with CellGenTech on a capital and business alliance in order to assist with rapid market penetration, such as market research before launch and appropriate use, popularization, edification and recruiting of patients after launch while utilizing the panel of 145,000 doctors who are members of CareNet in cooperation with CellGenTech, in line with the development stage. In the present investment, CareNet and Medical Incubator Japan K.K. (hereinafter MIJ), with which CareNet has already

signed a business cooperation contract (released on May 15, 2018), will invest in CellGenTech after mutual consultation. CareNet and MIJ will operationally assist venture companies that are expected to lead the therapeutic revolution with innovative technologies in the healthcare field in the aspects of funds, more efficient and accelerated clinical trials, and appropriate popularization. The present investment in CellGenTech, one of the foremost GMAC regenerative medicine companies in Japan, is one such activity, and we will support the future success of CellGenTech.

【Description of the business alliance】

Through the present alliance, CareNet and CellGenTech will establish appropriate use and popularization of the GMAC regenerative medicine that is being developed by CellGenTech, in a cooperative manner while utilizing the know-how of pharmaceutical information provision and education for doctors and pharmacists, as well as recruiting patients, that CareNet has fostered.

About CellGenTech



Name: CellGenTech, Inc.

Representative Director: Masashi Aso, President

Address: Chiba-dai Inohana Innovation Plaza #101 1-8-15, Inohana, Chuo-ku, Chiba-city, Chiba, Japan

Establishment: October 2003

Capital: 325 million yen

Major business activities: Development, manufacturing and marketing of regenerative cellular medicines

About CareNet



Name: CareNet, Inc.

Representative Director: Katsuhiko Fujii, President

Location: Risona-kudan Building, 1-5-6, Kudan-minami, Chiyoda-ku, Tokyo, Japan

Establishment: July 1996

Capital: 627 million yen

Major business activities: Medical and pharmaceutical business support for pharmaceutical companies and medical contents services for doctors and medical professionals.

CareNet operates a membership portal site “CareNet.com” to provide practical and useful information for doctors and medical professionals via internet, with more than 140,000 doctors as members. Based on these physician members as resources, CareNet provides services to support sales and marketing activities of pharmaceutical companies in Japan.

Future outlook

There is estimated to be little effect from the present business alliance on business performance in this term. Moving forwards, if any significant effect on our business performance that should be disclosed is considered likely, then it will immediately be disclosed.

—Contact for the present release—

Management Planning Division, CareNet, Inc.

[TEL: +81-3-5214-5800](tel:+81-3-5214-5800) MAIL: ir@carenet.co.jp